Search Results 1611-1620 of 16133 for chemoprevention

1. Housecall: Don't let jet lag drag you down

   Symptoms include daytime fatigue, an unwell feeling, difficulty staying alert and gastrointestinal problems. A few basic steps may prevent jet lag or reduce its ...

2. A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene - Mayo Clinic

   The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety of EPZ-5676 in patients with advanced hematologic malignancies, and ...

3. GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC - Mayo Clinic

   About this study. The purpose of this study is to evaluate whether CAN-2409 + prodrug added to standard of care immune checkpoint inhibitor (ICI) therapy ...

4. WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome - Mayo Clinic

   WEE1 inhibitor AZD1775 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ...

5. Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer that has been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) - Mayo Clinic

   Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments ...

6. Bortezomib, Rituximab, and Dexamethasone with or without Temsirolimus in Treating Patients with Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma - Mayo Clinic

   Bortezomib may also stop the growth of cancer cells by blocking blood flow to the tumor. Monoclonal antibodies, such as rituximab, can block cancer growth in ...

7. An Expanded Access Study of Iniparib Combined with Gemcitabine and Carboplatin for the Treatment of Breast Cancer - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

8. Vascular Diseases Biorepository - Atherosclerosis and Lipid Genomics Laboratory - Mayo Clinic Research

   Peripheral artery disease; Aortic aneurysm; Carotid artery stenosis; Fibromuscular dysplasia. In addition, electronic health record (EHR)-based algorithms are ...

9. Program Evaluation - Center for Clinical and Translational Science

   CCaTS Education Resources has a comprehensive system for evaluating its educational programs.

10. Expanding regenerative biotherapeutics to new practice areas - Mayo Clinic News Network

    Dr. Lin and the center's leadership will focus on accelerating biological therapies — medicines manufactured from human sources, such as cells, blood, tissue, ...